New imaging comparison could improve prostate cancer monitoring
NCT ID NCT06461689
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 80 patients with advanced prostate cancer that had stopped responding to chemotherapy. All patients received a radioactive drug called 177Lu-PSMA-617. Researchers compared two types of scans—PET and SPECT—to see which better tracks changes in tumor size and activity over time. The goal is to find the best way to monitor how well the treatment is working.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 177Lu-PSMA-617 (a radioactive drug)
- What this could lead to
- If successful, this could help doctors choose the best imaging method to monitor treatment response in advanced prostate cancer.
- What could go wrong
- This is a small, completed study that only looks at imaging data, not patient outcomes. The results may not change current practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
80 people
The number who actually took part.
- Started
-
Dec 2024
- Finished
-
Feb 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
All patients treated with 177Lu-PSMA had post-therapy 68Ga-PSMA PET and 177Lu-PSMA-617 SPECT/CT.
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patient who received a dose of 177lu-PSMA * patient who had imaging by 68Ga-PSMA * patient treated in Nancy hospital for its cancer prostate Exclusion Criteria: * no social security * no acceptation to participating in retrospective study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prostate cancer metastatic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU de NANCY
Vandœuvre-lès-Nancy, 54511, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells take down treatment-resistant prostate cancer?
- Can a new pill outsmart resistant prostate cancer?
- Could fasting help the immune system fight prostate cancer?
- Could a new PET tracer reveal hidden prostate cancer activity?
- AI reads biopsies to predict cancer spread
- AI learns from 14,000 prostate scans to spot aggressive cancers